MedWatch

Nordea is hot on Novo Nordisk

A recent announcement from the EMA that the agency discovered no increased risk of cancer from the class of drugs Novo Nordisk’s blockbuster Victoza belongs to will cause a rise in the price of the Danish company’s share, says Nordea.

Foto: Novo Nordisk/PR

Following a period of heavy debate, the European Medicines Agency (EMA) last Friday offered its support to Victoza and other GLP-1 drugs by ruling out an increased risk of pancreatic cancer from the medicine type. It is welcome news for Novo Nordisk, and it also supports what FDA has said in the matter previously.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier